By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Coherus Biosciences 

201 Redwood Shores Parkway
Suite 200
Redwood City  California  94065  U.S.A.
Phone: 800-794-5434 Fax: n/a



Company News
Coherus Biosciences Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy) 7/16/2014 9:32:29 AM
Coherus Biosciences Appoints Dr. V. Bryan Lawlis, Jr. To Board Of Directors 7/9/2014 10:20:08 AM
Coherus Biosciences Announces Initiation Of Phase 3 Trial Of Chs-0214 (Investigational Etanercept Biosimilar) In Rheumatoid Arthritis 6/23/2014 11:00:26 AM
Coherus Biosciences Appoints Vince R. Anicetti As Senior Vice President, Global Quality 6/9/2014 10:11:02 AM
Redwood City's Coherus Biosciences Locks In $55 Million Series C 5/19/2014 6:53:42 AM
Coherus Biosciences Appoints Lisa M. Bell, Ph.D., Senior Vice President, Global Regulatory Affairs 5/12/2014 6:43:55 AM
Coherus Biosciences Appoints Michael A. Fleming As Senior Vice President, Commercial Strategy 4/28/2014 8:43:33 AM
Coherus Biosciences Invited To Present At 2014 J.P. Morgan Annual Healthcare Conference 1/7/2014 8:06:33 AM
Coherus Biosciences Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study 10/28/2013 10:09:20 AM
Baxter International, Inc. (BAX) and Coherus Biosciences Sign $246 Million Biosimilars Pact 9/3/2013 8:01:07 AM